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Abstract
OBJECTIVE: To investigate the effect of a treat-
ment course of comprehensive intervention with
Traditional Chinese Medicine (TCM) on the mortali-
ty of patients with acquired immunodeficiency syn-
drome (AIDS) treated with combined antiretroviral
therapy (cART).
METHODS: AIDS patients who had taken cART in a
national TCM human immunodeficiency virus treat-
ment trial program (NTCMTP) before 2009 were en-
rolled in this study and followed for 36 months
from November 2009. Patients enrolled in the NTC-
MTP in 2004 were taken as the first group, those en-
rolled in 2006 as the second group, and those en-
rolled in 2009 as the third group. Cumulative surviv-
al rates were calculated by the life table method.
Survival curves for subgroups were compared by
the log-rank test. Hazard ratios were calculated
with a Cox proportional hazards model.
RESULTS: A total of 1443 AIDS patients were fol-
lowed for 3 years (4198 person-years). During this
period, 91 (6.3%) patients died and 13 (0.9%) were
lost to follow-up. The total mortality rate was 2.17/
100 person-years. The mortality rate of patients en-
rolled in the NTCMTP in 2004 was 1.49/100 per-
son-years, which was lower than that of patients en-
rolled in 2006 (2.23/100 person-years) and 2009
(3.48/100 person-years). After adjusting for other
factors, a shorter time of treatment with TCM, male
sex, older age, lower CD4 + T-cell counts, and
long-term treatment with cART were risk factors of
mortality.
CONCLUSION: Long-term treatment with TCM de-
creased the mortality risk of AIDS patients. Factors
such as being male, older age, CD4+ T-cell counts,
and time of treatment with TCM and cART were cor-
related with mortality.
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INTRODUCTION
At the end of 2012, the Joint UN Programme on hu-
man immunodeficiency virus (HIV)/acquired immuno-
deficiency syndrome (AIDS, UNAIDS) estimated that
there were 35.3 million people living with HIV (PL-
HIV) worldwide and an increasing number of PLHIV
received life-saving combined antiretroviral therapy
(cART).1 The advent of cART gave hope to PLHIV be-
cause it dramatically reduced disease progression and
death and improved patients' quality of life.2,3 Howev-
er, the side effects of cART, such as nausea, diarrhea, fa-
tigue, lipodystrophy, and skin problems, can result in
non-adherence to the treatment.4,5 The benefits of
cART were only achieved with a high level of adher-
ence,6 and less than optimal adherence was associated
with virologic failure and cART resistance.7-9 This clini-
cal dilemma has compelled researchers to find new
drugs or complementary treatments.
Over the last 30 years, Traditional Chinese Medicine
(TCM), a type of complementary medicine, has been
used to treat HIV. Studies show that TCM treatment
partially reduces plasma HIV viral load, increases
CD4+ T-cell counts, and promotes immunity reconsti-
tution, thus ameliorating symptoms and signs, improv-
ing health-related quality of life (HRQOL), and coun-
teracting the side effects of anti-retroviral drugs.10,11
In 2004, China' s State Administration of Traditional
Chinese Medicine started a national TCM HIV treat-
ment trial program (NTCMTP) that provided free
TCM treatment to 9267 PLHIV in 17 provinces (au-
tonomous regions and municipalities) by the end of
2009. As a province that began the NTCMTP early,
Henan province adopted a strategy called the "three
uniformities and three combinations principles" to
manage the NTCMTP. This approach included three
uniform aspects (unified organization, unified therapy,
and unified index) and three combined aspects (clinical
treatment combined with scientific research, fixed pre-
scription combined with dialectical treatment, and
TCM therapy combined with cART). All PLHIV in a
certain region could join the program voluntarily with-
out consideration of whether they had taken cART.
Once the PLHIV entered the NTCMTP, they would
come under the same management of the NTCMTP
and receive the same treatment. A case report form
would be established and the patient would receive free
TCM treatment monthly until they requested other-
wise. When patients had other symptoms, they would
be treated based on syndrome differentiation.12 Each
group of PLHIV entered the NTCMTP over a short
period of time, and from 2004 to 2009 there were
three batches of PLHIV enrolled in the NTCMTP in
Henan, in 2004, 2006, and 2009.
In this retrospective study, data from AIDS patients
treated with cART plus TCM comprehensive interven-
tion were analyzed, focusing on the effects of the treat-
ment course with a comprehensive TCM intervention
on mortality.
METHODS
Patients
The study population included AIDS patients aged be-
tween 18 and 65 who were identified as HIV-positive
by western blot analysis between November 2003 and
October 2004 and who took cART and were enrolled
in the NTCMTP before November 2009. Patients
who died before November 2009 or stopped taking
cART before November 2009 were excluded.
Patient data were collected at enrollment and monthly
thereafter, mainly through a case report form that in-
cluded demographic information, laboratory measure-
ments (i.e., CD4 + T-cell counts, whole blood cell
counts, urine analysis, liver and renal function, and
HIV viral load test results), detailed information on
therapy, clinical symptoms, and vital status in the
NTCMTP. In this cohort study, we followed the pa-
tients from November 2009 to November 2012. Pa-
tients enrolled in the NTCMTP in 2004 were taken as
the first group, those enrolled in 2006 formed the sec-
ond group, and those enrolled in 2009 formed the
third group.
The data analyzed in this study were mainly collected
from the NTCMTP database and checked against the
national surveillance system of HIV-infected patients
in the Chinese Centers for Disease Control (CDC).
Ethical considerations
This study was approved by the institutional review
board of the First Hospital affiliated to Henan Univer-
sity of Traditional Chinese Medicine. Individual in-
formed consent was not required because this analysis
used existing data collected during the course of rou-
tine treatment, and the data were reported in aggregate
without the use of individual identifying information.
Data analysis
The demographic characteristics of patients were col-
lected in November 2009 and analyzed by chi-squared
test or analysis of variance. The survival study followed
patients for 36 months from November 2009, with
death as the event of measure. Patients who were still
ailing at the end of follow-up, lost to follow-up, or
died because of a non-AIDS-related illness such as sui-
cide or accident were omitted from the results. If the
PLHIV did not return to pick up their medicine, medi-
cal workers would actively visit neighbors or relatives
to identify whether the patient had died or was lost to
follow-up.
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Cumulative survival rates were calculated by the life ta-
ble method. Survival curves for subgroups were com-
pared by the log-rank test. Crude and adjusted relative
hazards ratios were calculated with a Cox proportional
hazards model. All statistical analyses were performed
using IBM SPSS Statistics for Windows (Version 19.0,
IBMCorp., Armonk, NY, USA).Two-sided P-values less
than 0.05 were considered to be statistically significant.
RESULTS
Patients
A total of 1443 subjects met the inclusion criteria for
this study (Figure 1): 733 in the first group (enroll-
ment in the NTCMTP in 2004), 343 in the second
group (enrollment in 2006), and 367 in the third
group (enrollment in 2009). Among all groups, the
mean age was (46 ± 8) years and the majority were
farmers (1441/1443, 99.9%) of Han ethnicity (1442/
1443, 99.9%), and infected through the sale of blood
(1413/1443, 97.9% ). A comparison of demographics
between the three groups is shown in Table 1.
Mortality rate and cumulative survival
Of the 1443 AIDS patients who were followed for 3
years, 91 (6.3%) died and 13 (0.9%) were lost to fol-
low-up. Of the 13 lost to follow-up, six died because of
a non-AIDS-related illness such as suicide or accident,
three did not follow-up because they left their home
town to work, one left the trial because of drug side ef-
fects, and three were lost with no known reason. In to-
tal, the study followed 4198 person-years and the mor-
tality rate over the study period was 2.17/100 per-
son-years. The cumulative survival rates were 97.4%
and 93.6% in the first and third years, respectively.
In the first group, 733 patients were followed for 2147
person-years and by the end of follow-up 32 (4.4% )
had died and eight (1.1%) were lost to follow-up. In
the second group, 343 were followed for 988 per-
son-years, and by the end of follow-up 22 (6.4%) had
died and three (0.8% ) were lost to follow-up. In the
third group, 367 were followed for 1063 person-years,
and by the end of follow-up 37 (10.1%) had died and
two (0.5%) were lost to follow-up. Mortality rate over
the study period was 1.49/100 person-years, 2.23/100
person-years, and 3.48/100 person-years in the first,
second, and third groups, respectively.
The cumulative survival rates in the first, second, and
third groups were 98.2%, 95.9%, and 97.0%, respec-
tively, in the first year and 95.6%, 93.6%, and 89.9%
in the third year. The difference in cumulative survival
between the three groups was statistically significant
(Figure 2).
3371 HIV-positive individual registered in
the NTCMTP area by the end of 30 October
2009
41 aged < 18 years or > 65 years
430 died before 30 October 2009
2900 HIV-positive individual lived with
18-65 years in 30 October 2009
464 not take cART before 30 October 2009
219 stop taking cART after 30 October 2009
2217 HIV-positive individual have taken
cART during the study period
461 identified HIV-positive before 30
October 2003.
179 identified HIV-positive after 30 October
2004
1577 HIV-positive individual identified
HIV-positive in 2003- 2004
40 quit NTCMTP before 30 October 2009
94 with invalid information.
1443 AIDS patients met the inclusion criteria
in this study
Figure 1 Flow diagram of the study
NTCMTP: National Traditional Chinese Medicine Human Immunodeficiency Virus Treatment Trial Program; cART: combination anti-
retroviral therapy; AIDS: acquired immune deficiency syndrome; HIV: human immunodeficiency virus.
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Factors associated with AIDS-related death of
patients
The mortality of patients in the second group was 1.5
times higher [hazard ratio (HR): 1.59, 95% confidence
interval (CI; 0.87, 2.57)] and that in the third group
was 2.3 times higher [HR: 2.34, 95% CI (1.46, 3.76)]
than that in the first group. In addition, sex, age, and
CD4 cell counts were significant risk factors for mortal-
ity of AIDS patients by univariate analysis. After adjust-
ing for the other factors by multivariate Cox propor-
tional hazards model analysis, the risk of mortality was
1.7 times higher [HR: 1.74, 95% CI (1.00, 3.04)] in
the second group and 2.3 times higher [HR: 2.25,
95% CI (1.39, 3.63)] in the third group compared
with the first group. The multivariate analysis revealed
that sex, age, and duration of treatment were also asso-
ciated with mortality of patients. The mortality risk of
women was lower than that of men [HR: 0.62, 95%
CI (0.41, 0.96)]. Patients older than 50 years had a 3.5
times higher risk of mortality than those younger than
40 [HR: 3.52, 95% CI (1.81, 6.84)]. Compared with
patients who were treated with cART for less than 1
year, patients treated with cART for 3 to 5 years had a
3.0 times higher risk [HR: 3.04, 95% CI (1.07, 8.62)]
and those treated with cART for more than 5 years had
a 2.7 times higher risk [HR: 2.68, 95% CI (0.95,
7.53]. Patients with higher CD4+T cell counts had a
lower mortality risk. Detailed information is provided
in Table 2.
DISCUSSION
In this analysis, we enrolled PLHIV who had been
treated with cART in the NTCMTP as the study popu-
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Figure 2 Comparison of cumulative survival percent of AIDS
patients between three groups
First group: patients enrolled in a national TCM HIV treat-
ment trial program (NTCMTP) in 2004; Second group: pa-
tients enrolled in the NTCMTP in 2006; Third group: patients
enrolled in the NTCMTP in 2009.
Table 1 Characteristics of the patients in 2009 [n (%)]
Item
Sample size
Sex
Age (years)
Marital status
Education level
(years)
Years of
Treatment with
cART (years)
CD4+ T-cell
counts (cell/mm3)
Men
Women
<41
41-50
>50
Married
Single/Widow (er)
<6
>6
<1
>1-3
>3-5
>5
<200
201-350
>350
Unknown
xˉ ± s
Total sample
1443
665 (46.1)
778 (53.9)
365 (25.3)
625 (43.3)
453 (31.4)
1094 (75.8)
349 (24.2)
929 (64.4)
514 (35.6)
144 (10.0)
205 (14.2)
441 (30.6)
653 (45.3)
352 (24.4)
471 (32.6)
579 (40.1)
41 (2.8)
345±206
First group
733
335 (45.7)
398 (54.3)
192 (26.2)
320 (43.7)
221 (30.2)
562 (76.7)
171 (23.3)
463 (63.2)
270 (36.6)
54 (7.4)
66 (9.0)
214 (29.2)
399 (54.4)
179 (24.4)
232 (31.7)
306 (41.7)
16 (2.2)
356±215
Second group
343
160 (46.6)
183 (53.4)
85 (24.8)
151 (44.0)
107 (31.2)
269 (78.4)
74 (21.6)
253 (73.8)
90 (26.2)
57 (16.6)
77 (22.4)
103 (30.0)
106 (30.9)
80 (23.3)
126 (36.7)
119 (34.7)
18 (5.2)
323±191
Third group
367
170 (46.3)
197 (53.7)
88 (24.0)
154 (42.0)
125 (34.1)
263 (71.7)
104 (28.3)
213 (58.0)
154 (42.0)
33 (9.0)
62 (16.9)
124 (33.8)
148 (40.3)
93 (25.3)
113 (30.8)
154 (42.0)
7 (1.9)
345±199
Statistic
-
0.095
1.932
5.020
20.017
85.709
15.209
2.958
P value
-
0.954
0.748
0.081
0.001
0.001
0.019
0.052
Notes: first group: patients enrolled in national TCM HIV treatment trial program (NTCMTP) in 2004; second group: patients enrolled
in the NTCMTP in 2006; third group: patients enrolled in the NTCMTP in 2009. cART: combined antiretroviral treatment; M: mean;
SD: stander deviation.
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lation to document the outcome of different treatment
courses of TCM in terms of survival and investigate
the risk factors for mortality through a retrospective co-
hort study.
The patients in this study were identified between No-
vember 2003 and October 2004 and had been infected
with HIV for more than 10 years in 2009, when this
study was initiated. Although the CD4+ T cell count,
which was the prognostic index of AIDS, was not dif-
ferent between the three groups, the mortality rates
were significantly different. The 3-year mortality rates
were 4.4%, 6.4%, and 10.1% for the three groups en-
rolled in NTCMTP in 2004, 2006, and 2009, respec-
tively. The difference may be caused by the different in-
ternal environment of AIDS patients, which is called
Yuan Qi or Zheng Qi (Health Qi) in TCM theory. The
Yiaikang capsules (Henan Province Orient Pharmaceu-
tical Co., Ltd., Zhengzhou, China) taken by AIDS pa-
tients in NTCMTP of Henan might strengthen the
spleen and replenish Qi, Zi Yin Yang Xue (Nourish-
ing Yin and blood), expelling wind and clearing away
heat and Hua Shi Jie Du (resolving dampness and Re-
moving toxin). This might improve the immunity and
strengthen the yuan Qi (Health Qi) of AIDS patients.
The results of the NTCMTP of Henan showed that yi
ai kang capsules could relieve the clinical symptoms,
decrease opportunistic infection, and decrease the mor-
tality.13-18 The mortality rate of patients in the first
group, who had received TCM for 5 years, was 1.49/
100 person-years, lower than that of patients in the
other two groups who had taken TCM for 3 years or
less than 1 year. After adjusting for other confounding
factors, the risk of mortality was 1.7 times higher in
the second group and 2.3 times higher in the third
group than that of the first group. These results suggest
that long-term treatment with TCM decreases the mor-
tality risk of AIDS patients.
The 1443 AIDS patients were followed for 3 years, giv-
ing a total of 4198 person-years. The overall mortality
rate was 2.17/100 person-years, which is lower than
that of many other studies. The results of the free anti-
retroviral treatment plan in China showed that the
mortality rate of adults with AIDS was 5/100 per-
son-years after 6 months of treatment.19 A study from
Henan province showed a mortality rate of 5.1/100
person-years after cART.20 Another study of HIV-infect-
Table 2 Hazard ratios for variables of AIDS-related death of AIDS patients
Category
Group (n)
Sex (n)
Age (years)
Marital status (n)
Education level (years)
Treatment with ARV at
initiation (years)
CD4+ T cell counts (cell/mm3)
First group
Second group
Third group
Men
Women
<40
41-50
>50
Married
Single/Widow (er)
<6
>6
<1
1-3
3-5
>5
<200
201-350
>350
Unknown
Case
733
343
367
665
778
365
625
453
1094
349
929
514
144
205
441
653
352
471
579
41
Death
32
22
37
52
39
12
32
47
63
28
59
32
4
10
34
42
33
26
32
0
Unadjusted
cHR (95% CI)
1
1.50 (0.87-2.57)
2.34 (1.46-3.76)
1
0.64 (0.42-0.96)
1
1.58 (0.81-3.07)
3.25 (1.73-6.13)
1
1.40 (0.90-2.18)
1
0.98 (0.64-1.51)
1
1.75 (0.55-5.57)
2.79 (0.99-7.87)
2.39 (0.86-6.65)
1
0.57 (0.34-0.96)
0.57 (0.35-0.93)
-
P value
-
0.146
0.001
-
0.032
-
0.176
0.001
-
0.141
-
0.921
-
0.347
0.052
0.096
-
0.033
0.024
0.961
Adjusted
1
1.74 (1.00-3.04)
2.25 (1.39-3.63)
1
0.62 (0.41-0.96)
1
1.69 (0.86-3.29)
3.52 (1.81-6.84)
1
1.09 (0.68-1.73)
1
1.10 (0.70-1.74)
1
1.77 (0.56-5.66)
3.04 (1.07-8.62)
2.68 (0.95-7.53)
-
0.55 (0.33-0.92)
0.53 (0.32-0.87)
-
aHR (95% CI) P value
-
0.051
0.001
-
0.031
-
0.126
0.001
-
0.727
-
0.682
-
0.334
0.037
0.063
-
0.023
0.011
0.961
Notes: first group: patients enrolled in national TCM HIV treatment trial program (NTCMTP) in 2004; Second group: patients enrolled
in the NTCMTP in 2006; Third group: patients enrolled in the NTCMTP in 2009. AIDS: Acquired immunodeficiency syndrome;
cART: combined antiretroviral therapy; cHR: crude hazard ratio; aHR: adjusted hazard ratio; CI: confidence interval.
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ed patients who entered the NTCMTP in 2004 and
were followed for 6 years showed a mortality rate of
3.6/100 person-years.17 This difference may reflect the
less advanced clinical stage of AIDS patients in the lat-
ter study. Mean CD4 cell count was 344.6 cells/mm3,
higher than that of previous studies, which was 301
cells/mm3 or less than 200 cells/mm3.17,19,20 Age, sex, ed-
ucation, race, HIV transmission, and CD4 T lympho-
cyte cell counts have been associated with the survival
of AIDS patients.21-26 In our study, women had a lower
risk of mortality than men, which was in accordance
with many studies in China.20,23 Older age and lower
CD4+T cell counts were associated with a higher risk
of death, which is also consistent with other studies.21-26
Our results did not show a lower mortality rate for the
AIDS patients who took cART earlier, as reported in
many studies,27 because the criterion for receiving
cART free of charge was different. The patients who re-
ceived cART later may have had less advanced clinical
stages and higher CD4+T cell counts.28
The results of our study suggest that the mortality risk
of AIDS patients was decreased with long-term treat-
ment with TCM. However, as a retrospective study it
has some limitations. In particular, the PLHIV were
not randomly enrolled in the NTCMTP, which could
lead to selection bias. Further research is needed to con-
firm these results.
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